Like other cannabinoids, delta-8 appears to have anxiolytic (anxiolytic) properties. In a survey, 69% of D8 users said they used the cannabinoid primarily to control anxiety and panic attacks. And 52% reported using it to reduce stress. The.
gov means it's official, federal government websites often end in. Gov or. thousand. Before sharing sensitive information, make sure you're on a federal government site.
It's important for consumers to know that delta-8 THC products have not been evaluated or approved by the FDA for safe use in any context. They can be marketed in ways that jeopardize public health and, especially, should be kept out of reach of children and pets. The FDA is aware of the growing concern surrounding delta-8 THC products currently being sold online and in stores. The FDA has not evaluated or approved these products for safe use in any context.
Some concerns include the variability in product formulations and labeling, the content of other cannabinoids and terpenes, and the varying THC concentrations of delta-8. In addition, some of these products may simply be labeled as “hemp products”, which can mislead consumers who associate “hemp” with “non-psychoactive products”. In addition, the FDA is concerned about the proliferation of products that contain delta-8 THC and that are marketed for therapeutic or medical purposes, even if they have not been approved by the FDA. Selling unapproved products with unsubstantiated therapeutic claims not only violates federal law, but it can also put consumers at risk, since these products have not been proven to be safe or effective.
This misleading advertising of unproven treatments raises significant public health problems, as patients and other consumers can use them instead of approved therapies to treat serious and even fatal diseases. Delta-8 THC has psychoactive and intoxicating effects, similar to those of delta-9 THC (that is, the FDA is aware of media reports about delta-8 THC products that cause consumers to “get high”). The FDA is also concerned that delta-8 THC products may expose consumers to much higher levels of the substance than those found naturally in raw hemp and cannabis extracts. Therefore, the historical use of cannabis cannot be relied upon to establish a level of safety for these products in humans.
The FDA is actively working with federal and state partners to further address concerns related to these products and to monitor the market for complaints about products, adverse events, and other emerging cannabis-derived products that may be a cause for concern. The FDA will warn consumers about public health and safety issues and will take necessary action when products regulated by the FDA violate the law. The American Association of Poison Control Centers (AAPCC) maintains the National Poison Data System (NPDS), which contains anonymous case records of self-reported information collected from callers during exposure control and poison information calls managed by the country's poison control centers (PCC). NPDS data do not reflect the entire universe of exposures to a particular substance, since additional exposures to PCC may not be reported; therefore, NPDS data should not be interpreted as representing the total incidence of U.S.
UU. Exposures do not necessarily represent poisoning or overdose, and the AAPCC cannot fully verify the accuracy of each report. Findings based on NPDS data do not necessarily reflect the views of the AAPCC. Sign up for email notifications from the FDA Consumer Update.
CBD is also more commonly used to alleviate anxiety and insomnia, and delta-8 is more commonly used to relax and achieve euphoria...